

ALINA Newsletter

Edition 1 | June 2022

We are in the fourth year of our study and the ALINA family has **257** participants from **26** countries!



Around **60%** of the participants have completed their treatment cycles and entered the follow-up/long term follow-up stage.

Table of contents	#
The study and your contribution	1
Your participation and useful tips	2-3
FAQs and references	4

The importance of research and your participation in the ALINA study

Your contributions to research



Every single visit is important, as missing or incorrect data may affect the results of this study

Your participation and your study data will contribute to the results and conclusion for the study



Data from every participant is important!

The effects of alectinib and chemotherapy will be compared in this study

Your well-being is our top priority! To support this, please remember to:



Ask questions and discuss any concerns with the study team



Take the treatment as instructed and follow the study team's advice

*Thank you for taking part in the ALINA study!
Your participation is vital to our research into ALK+ NSCLC*

Things to note about your study participation

Your participation should be as easy as possible. Please ask your study team what is available at your site to improve your study experience!



Disease assessment appointments every three or six months depending on how much time passed since you joined the study
Until the study is complete or disease comes back



Long-term follow-up
If the disease comes back



Rescheduling appointments
Days or times that are most convenient for you.
This includes updates **due to travel, vacations or moves**



Have a friend or family assist you at visits
Help you throughout your appointment



Support is available for the ALINA patients
Study visit travel and meal expenses reimbursement are available as per local arrangements, please speak with your study team

Balancing study participation and your life

Here are some things to consider as you balance study participation and day today life.



Managing your health and safety

Share with your family or friends if you are feeling tired or would like some help with your daily tasks



Reach out to the study team if you simply want to talk to someone about how you are feeling



Remember to **schedule some time just for you** and do something that makes you feel good



We encourage you to **continue to visit the study site to have your health and safety closely monitored** until the study ends



Let your study team know if you have any questions about the study assessments or the study medication



A moderate amount of **exercise can be beneficial** to your physical and mental health, please speak with your study doctor

FAQs



What should I do if I see another doctor?

For safety reasons, it is important that you inform any doctors or other healthcare professionals of your participation in the ALINA study. It is important to also inform your study doctor at the earliest opportunity.

What should I do if I want to take a new medication?

Please talk to your study doctor if you are considering a new medication. Your study team will address any concerns you may have and discuss your treatment options.

What do I do if I cannot attend a study appointment?

If you cannot attend a study appointment, contact your study doctor as soon as possible to reschedule. They will work with you to find a time that is more convenient.

What do I do if I experience side effects?

It is important that you tell your study doctor immediately if you are having any side effects. If this were to happen you will receive appropriate medical attention. Please talk to your study doctor regarding treatment options.

Can I stop participating at any time?

Yes. Participation is voluntary, which means you may stop taking the study drug or withdraw from the study completely at any time for any reason. However, if you are experiencing any hesitations or doubts, please reach out to your study doctor as soon as possible. If you agree, your study doctor will continue to monitor your safety even if you stop taking the study drug.